Home
JNJ
JNJ News

Latest Johnson & Johnson (JNJ) News on July 12, 2025

MT Newswires

19 hours ago

HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating

3 AI-Driven Medical Device Stocks to Watch in 2025

Zacks

20 hours ago

3 AI-Driven Medical Device Stocks to Watch in 2025

Johnson & Johnson (JNJ) Declined Amid Broad Sell-Off in Healthcare

Insider Monkey

21 hours ago

Johnson & Johnson (JNJ) Declined Amid Broad Sell-Off in Healthcare

Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments

GlobeNewswire

a day ago

Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments

Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma

GlobeNewswire

a day ago

Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

Motley Fool

a day ago

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data

Insider Monkey

2 days ago

Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data

UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

Insider Monkey

2 days ago

UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

MT Newswires

2 days ago

Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

Reuters

3 days ago

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

Wall Street waves off Trump's 200% pharma tariff threat

Yahoo Finance

3 days ago

Wall Street waves off Trump's 200% pharma tariff threat

MT Newswires

3 days ago

Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

3 days ago

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Zacks

3 days ago

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Merck Faces Multiple Challenges: Will It Steer Through Successfully?

Zacks

3 days ago

Merck Faces Multiple Challenges: Will It Steer Through Successfully?

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

Zacks

3 days ago

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

SpaceX Just Made Elon Musk $20 Billion Richer

Barrons.com

3 days ago

SpaceX Just Made Elon Musk $20 Billion Richer

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

Zacks

3 days ago

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage

Insider Monkey

3 days ago

Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage

MT Newswires

4 days ago

Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs

Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA

Simply Wall St.

4 days ago

Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA

MT Newswires

4 days ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

MT Newswires

4 days ago

Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

Zacks

4 days ago

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

PR Newswire

4 days ago

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Analysis: 'Trump Effect' website takes credit for US investment made under Biden

Reuters

4 days ago

Analysis: 'Trump Effect' website takes credit for US investment made under Biden

Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock

Zacks

5 days ago

Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock

Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

Zacks

5 days ago

Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

J&J’s Abiomed recalls heart pump controllers after 3 patients die

MedTech Dive

5 days ago

J&J’s Abiomed recalls heart pump controllers after 3 patients die

Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?

Motley Fool

5 days ago

Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?

J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ)

Insider Monkey

6 days ago

J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ)

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

8 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE

GlobeNewswire

8 days ago

North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE

Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds

Insider Monkey

8 days ago

Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds

Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

Zacks

9 days ago

Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

Johnson & Johnson (JNJ) Could Be a Great Choice

Zacks

9 days ago

Johnson & Johnson (JNJ) Could Be a Great Choice

MT Newswires

9 days ago

Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer

The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle

Zacks

9 days ago

The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

Zacks

9 days ago

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

GlobeNewswire

9 days ago

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE

Zacks

9 days ago

MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

Pharmaceutical Technology

9 days ago

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

Top Analyst Reports for Johnson & Johnson, Home Depot and Micron

Zacks

9 days ago

Top Analyst Reports for Johnson & Johnson, Home Depot and Micron

Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Zacks

10 days ago

Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Zacks

10 days ago

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

A Promising Depression Drug Works. Psychedelics Are Back.

Barrons.com

11 days ago

A Promising Depression Drug Works. Psychedelics Are Back.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Zacks

11 days ago

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Zacks

11 days ago

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Zacks

11 days ago

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

PJM Appoints Deena O'Brien as Senior Director of Communications

PR Newswire

12 days ago

PJM Appoints Deena O'Brien as Senior Director of Communications

The Hackett Group® Announces Winners of the 2025 Hackett Innovation Awards

Business Wire

12 days ago

The Hackett Group® Announces Winners of the 2025 Hackett Innovation Awards

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

CNW Group

12 days ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control

Insider Monkey

14 days ago

Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Barchart

15 days ago

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever

Motley Fool

16 days ago

Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever

Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements

GlobeNewswire

16 days ago

Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements

Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial

Insider Monkey

17 days ago

Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial

Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US

Insider Monkey

17 days ago

Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US

Johnson & Johnson MedTech Expands VOLT Platform With New Wrist, Upper Arm Fracture Systems

Insider Monkey

17 days ago

Johnson & Johnson MedTech Expands VOLT Platform With New Wrist, Upper Arm Fracture Systems

J&J (JNJ) Faces $8M Verdict Over Talc Case; Stock Still Gains 4.66% YTD

Insider Monkey

17 days ago

J&J (JNJ) Faces $8M Verdict Over Talc Case; Stock Still Gains 4.66% YTD

Johnson & Johnson announces new data presented at EAN of IMAAVY

TipRanks

18 days ago

Johnson & Johnson announces new data presented at EAN of IMAAVY

MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

Zacks

18 days ago

MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?

Zacks

18 days ago

Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?

5 Dividend Stocks Poised to Profit From the AI Efficiency Boom

Motley Fool

18 days ago

5 Dividend Stocks Poised to Profit From the AI Efficiency Boom

J&J introduces disposable contact lens for astigmatism and presbyopia

Medical Device Network

18 days ago

J&J introduces disposable contact lens for astigmatism and presbyopia

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

Bloomberg

19 days ago

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

19 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

Zacks

19 days ago

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications

Zacks

19 days ago

J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications

MT Newswires

19 days ago

Johnson & Johnson's Imaavy Shows 'Significant Improvement' Over Other Treatments for Autoimmune Disorder

Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM

PR Newswire

19 days ago

Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

PR Newswire

19 days ago

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson

Zacks

19 days ago

Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Benzinga

21 days ago

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

JNJ’s Consistent Payout Makes It a Top Pick for Down Markets

Insider Monkey

21 days ago

JNJ’s Consistent Payout Makes It a Top Pick for Down Markets

IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant

GlobeNewswire

22 days ago

IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant

Johnson & Johnson (NYSE:JNJ) Faces US$8 Million Verdict Over Talcum Powder Cancer Case

Simply Wall St.

23 days ago

Johnson & Johnson (NYSE:JNJ) Faces US$8 Million Verdict Over Talcum Powder Cancer Case

$J&J MedTech introduces new plates for VOLT fracture management platform$

Medical Device Network

23 days ago

J&J MedTech introduces new plates for VOLT fracture management platform

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Zacks

23 days ago

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Trump administration weighs crackdown on pharma ads, Bloomberg says

TipRanks

24 days ago

Trump administration weighs crackdown on pharma ads, Bloomberg says

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Zacks

24 days ago

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions

Medical Device Network

24 days ago

Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions

2 Dividend Stocks to Buy and Never Sell

Motley Fool

24 days ago

2 Dividend Stocks to Buy and Never Sell

Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)

Motley Fool

24 days ago

Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)

Trump's big beautiful bill: What the pharma industry is watching

Yahoo Finance Video

24 days ago

Trump's big beautiful bill: What the pharma industry is watching

Johnson & Johnson’s Q1 Earnings Call: Our Top 5 Analyst Questions

StockStory

25 days ago

Johnson & Johnson’s Q1 Earnings Call: Our Top 5 Analyst Questions

MT Newswires

25 days ago

Market Chatter: Trump Administration to Consider Pharma Advertising Crackdown

ISRG's Minimally Invasive Ecosystem Powers Surgical Precision

Zacks

25 days ago

ISRG's Minimally Invasive Ecosystem Powers Surgical Precision

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

Zacks

25 days ago

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?

Zacks

a month ago

Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?

J&J reports results from antibody combo trial for MM patients

Clinical Trials Arena

a month ago

J&J reports results from antibody combo trial for MM patients

MT Newswires

a month ago

Johnson & Johnson Says Drug Combo Study Shows 'Deep, Durable' Responses Multiple Myeloma Patients With Extramedullary Disease

Pharma manufacturing 'boom' faces high costs, potential delays

Yahoo Finance

a month ago

Pharma manufacturing 'boom' faces high costs, potential delays

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

PR Newswire

a month ago

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma

Simply Wall St.

a month ago

Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Insider Monkey

a month ago

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)

TipRanks

a month ago

Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)

MT Newswires

a month ago

Sector Update: Health Care Stocks Softer Friday Afternoon

Senators to propose ban on drug ads to consumers, WSJ reports

TipRanks

a month ago

Senators to propose ban on drug ads to consumers, WSJ reports

MT Newswires

a month ago

Johnson & Johnson Says Therapy Shows 'Encouraging' First Trial Results in Large B-cell Lymphoma

Share on Social Networks: